{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:10Z","timestamp":1789753390980,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.intimp.2023.109829","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T10:33:53Z","timestamp":1675766033000},"page":"109829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin \u03b11"],"prefix":"10.1016","volume":"116","author":[{"given":"Nadav","family":"Nevo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lee Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshi","family":"Bar-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Abu-Abeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danit","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-2372","authenticated-orcid":false,"given":"Eran","family":"Nizri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2023.109829_b0005","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal carcinomatosis from colorectal cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.intimp.2023.109829_b0010","doi-asserted-by":"crossref","unstructured":"J, Franko, Q, Shi, J.P, Meyers, T.S, Maughan, R.A, Adams, M.T, Seymour, L, Saltz, C.J.A, Punt, M, Koopman, C, Tournigand, N.C, Tebbutt, E, Diaz-Rubio, J, Souglakos, A, Falcone, B, Chibaudel, V, Heinemann, J, Moen, A, De Gramont, D.J, Sargent, A, Grothey, Analysis, G. Research in Cancers of the Digestive System, Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database, Lancet Oncol 17(12) (2016) 1709-1719.","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"10.1016\/j.intimp.2023.109829_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010\u20132015","volume":"100","author":"Baratti","year":"2016","journal-title":"A systematic rev., Crit. Rev.. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2023.109829_b0020","doi-asserted-by":"crossref","unstructured":"F, Quenet, D, Elias, L, Roca, D, Goere, L, Ghouti, M, Pocard, O, Facy, C, Arvieux, G, Lorimier, D, Pezet, F, Marchal, V, Loi, P, Meeus, B, Juzyna, H, de Forges, J, Paineau, O, Glehen, U.-G, Group, B.I.G.R, Group, Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol 22(2) (2021) 256-266.","DOI":"10.1016\/S1470-2045(20)30599-4"},{"issue":"1","key":"10.1016\/j.intimp.2023.109829_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10304","key":"10.1016\/j.intimp.2023.109829_b0030","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.intimp.2023.109829_b0035","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.intimp.2023.109829_b0040","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.21.02691","article-title":"Mismatch repair-deficient colorectal cancer: building on checkpoint blockade","volume":"40","author":"Jin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109829_b0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109829_b0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109829_b0055","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fonc.2019.00873","article-title":"A reappraisal of thymosin alpha1 in cancer therapy","volume":"9","author":"Costantini","year":"2019","journal-title":"Front. Oncol."},{"issue":"13\u201314","key":"10.1016\/j.intimp.2023.109829_b0060","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/0959-8049(95)00477-7","article-title":"Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a","volume":"31A","author":"Garaci","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2023.109829_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109166","article-title":"Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma","volume":"111","author":"Nevo","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109829_b0070","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from the american society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109829_b0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-017-6237-0","article-title":"T-Helper 1 immune response in metastatic lymph nodes of pancreatic ductal adenocarcinoma: a marker for prolonged survival","volume":"25","author":"Nizri","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109829_b0080","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2023.109829_b0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s002620050562","article-title":"Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery","volume":"48","author":"Silecchia","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.intimp.2023.109829_b0090","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2003-11-4036","article-title":"Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling","volume":"103","author":"Romani","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.109829_b0095","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1517\/14712598.2015.1008446","article-title":"Evaluation of thymosin alpha 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis","volume":"15","author":"King","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.109829_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2021.05.023","article-title":"The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)","author":"van de Vlasakker","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.intimp.2023.109829_b0105","doi-asserted-by":"crossref","unstructured":"R, Helderman, D.R, Loke, P.J, Tanis, J.B, Tuynman, W, Ceelen, I.H, de Hingh, K, van der Speeten, N.A.P, Franken, A.L, Oei, H.P, Kok, J, Crezee, Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges, Cancers (Basel) 13 14 2021.","DOI":"10.3390\/cancers13143430"},{"issue":"3","key":"10.1016\/j.intimp.2023.109829_b0110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","article-title":"Targeting the tumor microenvironment in colorectal peritoneal metastases","volume":"6","author":"Ceelen","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2023.109829_b0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/onc.2015.82","article-title":"Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90","volume":"35","author":"Zunino","year":"2016","journal-title":"Oncogene"},{"issue":"45","key":"10.1016\/j.intimp.2023.109829_b0120","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"PNAS"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T12:25:14Z","timestamp":1719231914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":24,"alternative-id":["S1567576923001522"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109829","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin \u03b11","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109829"}}